Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB DEX versus CORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB DEX versus CORMAX.
AEROSEB-DEX vs CORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
2 puffs (100 mcg each) intranasally twice daily
2.5 mg orally twice daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Renal: 90% unchanged; minor biliary/fecal: <5%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid